key: cord-1029200-fd181r91 authors: Lou‐Mercadé, A. C.; Gavín, O.; Oros, D.; Paules, C.; Savirón‐Cornudella, R.; Mateo, P.; Páramo, J. A.; Ruiz‐Martinez, S. title: Prevention of thrombosis in pregnant women with suspected SARS‐CoV‐2 infection: clinical management algorithm date: 2020-05-25 journal: Ultrasound Obstet Gynecol DOI: 10.1002/uog.22096 sha: bd76a3e7c9c5182ce8acb25d011b5e93b0ee67d6 doc_id: 1029200 cord_uid: fd181r91 nan An emerging body of evidence suggests that COVID-19 may predispose patients to venous thromboembolism (VTE). Increased levels of D-dimer are associated with a worsening condition of the patient. Risk-assessment for VTE in all patients with COVID-19 admitted to hospital is recommended. Most cases of COVID-19 during pregnancy are mild or asymptomatic and clinical findings are similar to those of non-pregnant adults. However, pregnancy itself alters the body's immune system and the response to a viral infection can cause more severe symptoms. Recent reports warn of rapid maternal deterioration, coagulopathy 1 and maternal death among pregnant women diagnosed with COVID-19 disease 2 . In pregnant women, the physiological hypercoagulability state and the virus-related hypercoagulability could pose a uniquely increased risk for thrombotic-related morbidity. Thus, identifying women at risk is important for successful provision of appropriate prophylaxis. VTE risk assessment is complex as pre-existing conditions together with new onset or temporary risk factors must be evaluated. Reduced mobility due to home confinement or hospital admission and pneumonia are associated with increased risk of VTE in pregnant women. Multiple risk-assessment models have been developed to help estimate VTE risks in this population. A software tool, named AnticoagObs, based on international guidelines 3,4 is available via free access (http://www.anticoagulationinpregnancy.com/). International institutions 5 recommend antenatal and postnatal prophylactic LMWH in SARS-CoV-2 positive women. However, recommendations for some scenarios such as SARS-CoV-2-exposure (close contact with a confirmed case) and/or suspected-COVID-19 (symptoms consistent with COVID-19, persons under investigation) remain to be determined. A national expert committee endorsed by the Spanish Society of Thrombosis and Haemostasis, has built an algorithm for clinical management of pregnancy-associated VTE adapted to the current SARS-CoV-2 pandemic (appendix 1). It is important to update VTE risk factors that may worsen the severity of COVID-19 disease in pregnant women. Due to its role in promoting hypercoagulability, SARS-CoV-2 infection is included as an independent risk factor for VTE. We propose: 1) for asymptomatic women with SARS-CoV-2-exposure: re-assess for VTE risk factors during pregnancy and puerperium, give recommendations for isolation at home, and instruct the patient to contact a healthcare center or maternity unit if symptoms appear. 2) For women suspected of COVID-19 with mild to moderate symptoms: re-assess VTE risk factors and clinical severity and monitor at home every 48-72 h (telephone contact). Pregnant women hospitalized for suspected COVID-19 with severe symptoms, or any obstetric complications, should be given prophylactic weight-adjusted dose of heparin during admission and 1 month after discharge to prevent VTE. Due to greater risk of VTE during the third trimester, consider extending prophylaxis until delivery plus 6 weeks postpartum. Severe illness in suspected-COVID-19 patient should be managed as a confirmed SARS-CoV-2 infection. This algorithm includes, for the first time, an approach for thromboprophylaxis for ambulatory and hospitalized patients with SARS-CoV-2 exposure and suspected COVID-19. Careful monitoring of pregnancies with COVID-19 to prevent major complications such as VTE is warranted. Antithrombotic and anti-inflammatory properties of heparin may improve disease outcomes, providing that use of heparin is safe for the mother and the foetus. COVID19 and acute coagulopathy in pregnancy Maternal Death Due to COVID-19 Disease Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. (Green-top Guideline No. 37a). Royal College of Obstetricians and Gynaecologist American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Information for healthcare professionals C. Paules and S. Ruiz-Martinez were supported by a research grant from the Instituto de Salud Carlos III (CM18/00202, JR19/00006).